Impact of M184V on the Virological Efficacy to 3TC/DTG (LAMRES) (LAMRES)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04568239 |
|
Recruitment Status :
Recruiting
First Posted : September 29, 2020
Last Update Posted : July 22, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
In view of the prolongation of patients living with HIV's life expectancy, the question of optimization of ART, which is still a life-long treatment, becomes central. While most patients achieve virological success, their treatments often need to be optimized in order to limit adverse events, drugs interactions and to improve adherence. The switch to dual regimen strategies represent one of the approaches for treatment optimization. Indeed, dual therapy regimens have shown non-inferior efficacy vs triple therapy as simplification therapy and more recently also as first line therapy. From the real-life data it emerges that today in simplification strategies, the dual regimen therapies are prescribed even in patients with a history of virological failure. Circulating HIV-1 resistant variants can be archived in viral reservoirs, where they can persist for years and can reemerge in case of therapeutic selective pressure. In particular, previous selection of M184V may have an impact on virological response to 3TC/DTG. There are few data on a direct comparison of 3TC/DTG efficacy in patients harboring or not harboring the M184V. So, there is a need to assess the efficacy of 3TC/DTG in patients with past M184V mutation in a large set of patients followed in clinical setting.
Thus, the investigators propose a retrospective study of patients with HIV-RNA ≤50 copies/mL who were switched to 3TC/DTG in order to compare the virological efficacy of 3TC/DTG in patients with and without a history of M184V detection in a previous resistance genotype. This study aimed to analyze 800 patients switched to DTG/3TC in clinical real setting in large European (France, Italy, Spain) database.
| Condition or disease |
|---|
| HIV-1-infection |
| Study Type : | Observational |
| Estimated Enrollment : | 800 participants |
| Observational Model: | Case-Only |
| Time Perspective: | Retrospective |
| Official Title: | Impact of M184V on the Virological Efficacy to Lamivudine/Dolutegravir |
| Actual Study Start Date : | September 1, 2020 |
| Estimated Primary Completion Date : | December 1, 2022 |
| Estimated Study Completion Date : | December 15, 2023 |
| Group/Cohort |
|---|
| M184V + group and M184 - group |
- probability of virological failure [ Time Frame: 12 months ]probability of virological failure that is defined as HIV-RNA >50 copies/mL in 2 consecutive determinations or ≥200 copies/mL in a single determination. This outcome will be evaluated overall and between the M184V- and M184V+ patients' groups.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
HIV-1-infected patients with (i) age ≥18 years, (ii) HIV-RNA ≤50 copies/mL on any ART regimen, (iii) subsequently switching to DTG/3TC, (iv) with at least 1 previous plasma HIV-1 RNA or HIV-DNA genotype, (v) with at least 1 virological and clinical follow-up after switching to DTG/3TC.
The occurrence of M184V will be assessed using historical genotypic resistance tests; that is, any detection of this mutation in any previous resistance test will be scored as positive.
Inclusion Criteria:
- HIV-1 infected
- Age ≥ 18 years
- Switched to 3TC/DTG while having HIV-RNA ≤50 copies/mL on any ART regimen
- Followed for at least 1 year after 3TC/DTG switch
- With at least 1 previous genotype
- With at least 1 virological follow-up after switching to 3TC/DTG
Exclusion Criteria:
- No genotypic resistance test available before switching to DTG/3TC
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04568239
| Contact: Anne-Genevieve Marcelin, PharmD, PhD | +33142177401 | anne-genevieve.marcelin@aphp.fr | |
| Contact: Eve Todesco, PharmD, PhD | +33142177401 | eve.todesco@aphp.fr |
| France | |
| ARVD | Recruiting |
| Paris, France | |
| Contact: Anne-Geneviève MARCELIN anne-genevieve.marcelin@aphp.fr | |
| Principal Investigator: | Anne-Genevieve Marcelin, PharmD, PhD | Sorbonne University; APHP |
| Responsible Party: | Association de Recherche en Virologie et Dermatologie |
| ClinicalTrials.gov Identifier: | NCT04568239 |
| Other Study ID Numbers: |
ARVD-LAMRES |
| First Posted: | September 29, 2020 Key Record Dates |
| Last Update Posted: | July 22, 2021 |
| Last Verified: | July 2021 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
| Product Manufactured in and Exported from the U.S.: | No |